Allogene Therapeutics, Inc. Operating Lease Cost
Allogene Therapeutics, Inc. (ALLO) reported Operating Lease Cost of $2.33 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-12
- Allogene Therapeutics, Inc. operating lease, cost for the quarter ending 2026-06-30 was $2.33M, a 7.25% decline year-over-year.
- Allogene Therapeutics, Inc. operating lease, cost for the quarter ending 2026-03-31 was $2.34M, a 7.17% decline year-over-year.
- Allogene Therapeutics, Inc. operating lease, cost for the quarter ending 2025-12-31 was $2.37M, a 6.70% decline year-over-year.
- Allogene Therapeutics, Inc. operating lease, cost for the quarter ending 2025-09-30 was $2.37M, a 18.28% decline year-over-year.
- Allogene Therapeutics, Inc. operating lease, cost for fiscal 2025 was $9.77M, a 14.77% decline from fiscal 2024.
- Allogene Therapeutics, Inc. operating lease, cost for fiscal 2024 was $11.47M, a 9.78% decline from fiscal 2023.
- Allogene Therapeutics, Inc. operating lease, cost for fiscal 2023 was $12.71M, a 8.98% increase from fiscal 2022.
- Allogene Therapeutics, Inc. operating lease, cost for fiscal 2022 was $11.66M, a 55.25% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 3 month as first filed | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $2.33M 10-Q · filed 2026-08-12 | $4.67M 10-Q · filed 2026-08-12 | $7.04M derived: sum of 3 quarters · filed 2026-08-12 | $9.41M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | $2.34M 10-Q · filed 2026-05-13 | $4.71M derived: sum of 2 quarters · filed 2026-05-13 | $7.08M derived: sum of 3 quarters · filed 2026-05-13 | $9.59M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | $2.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $4.74M derived: sum of 2 quarters · filed 2026-03-12 | $7.25M derived: sum of 3 quarters · filed 2026-08-12 | $9.77M 10-K · filed 2026-03-12 | |
| 2025-09-30 | $2.37M 10-Q · filed 2025-11-06 | $4.88M derived: sum of 2 quarters · filed 2026-08-12 | $7.41M 10-Q · filed 2025-11-06 | $9.94M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | $2.51M 10-Q · filed 2026-08-12 | $2.51M 10-Q · filed 2025-08-13 | $5.04M 10-Q · filed 2026-08-12 | $7.57M derived: sum of 3 quarters · filed 2026-08-12 | $10.47M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $2.52M 10-Q · filed 2026-05-13 | $5.06M derived: sum of 2 quarters · filed 2026-05-13 | $7.96M derived: sum of 3 quarters · filed 2026-05-13 | $10.97M derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | $2.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $5.44M derived: sum of 2 quarters · filed 2026-03-12 | $8.45M derived: sum of 3 quarters · filed 2026-03-12 | $11.47M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $2.90M 10-Q · filed 2025-11-06 | $5.91M derived: sum of 2 quarters · filed 2025-11-06 | $8.93M 10-Q · filed 2025-11-06 | $12.11M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $3.01M 10-Q · filed 2025-08-13 | $6.03M 10-Q · filed 2025-08-13 | $9.21M derived: sum of 3 quarters · filed 2025-08-13 | $12.39M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $3.02M 10-Q · filed 2025-05-13 | $6.20M derived: sum of 2 quarters · filed 2025-05-13 | $9.38M derived: sum of 3 quarters · filed 2025-05-13 | $12.55M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | $3.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $6.36M derived: sum of 2 quarters · filed 2025-03-13 | $9.53M derived: sum of 3 quarters · filed 2025-03-13 | $12.71M 10-K · filed 2025-03-13 | |
| 2023-09-30 | $3.18M 10-Q · filed 2024-11-07 | $6.36M derived: sum of 2 quarters · filed 2024-11-07 | $9.54M 10-Q · filed 2024-11-07 | $12.72M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $3.17M 10-Q · filed 2024-08-07 | $6.36M 10-Q · filed 2024-08-07 | $9.54M derived: sum of 3 quarters · filed 2024-08-07 | $12.72M derived: sum of 4 quarters · filed 2024-08-07 | |
| 2023-03-31 | $3.18M 10-Q · filed 2024-05-13 | $6.37M derived: sum of 2 quarters · filed 2024-05-13 | $9.55M derived: sum of 3 quarters · filed 2024-05-13 | $12.72M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | $3.19M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $6.37M derived: sum of 2 quarters · filed 2024-03-14 | $9.54M derived: sum of 3 quarters · filed 2024-03-14 | $11.66M 10-K/A · filed 2024-03-14 | |
| 2022-09-30 | $3.18M 10-Q · filed 2023-11-02 | $6.35M derived: sum of 2 quarters · filed 2023-11-02 | $8.48M 10-Q · filed 2023-11-02 | $10.42M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-06-30 | $3.18M 10-Q · filed 2023-08-02 | $5.30M 10-Q · filed 2023-08-02 | $7.24M derived: sum of 3 quarters · filed 2024-03-14 | $9.10M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-03-31 | $2.12M 10-Q · filed 2023-05-03 | $4.07M derived: sum of 2 quarters · filed 2024-03-14 | $5.92M derived: sum of 3 quarters · filed 2024-03-14 | $7.77M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-12-31 | $1.95M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $3.80M derived: sum of 2 quarters · filed 2024-03-14 | $5.65M derived: sum of 3 quarters · filed 2024-03-14 | $7.51M 10-K/A · filed 2024-03-14 | |
| 2021-09-30 | $1.85M 10-Q · filed 2022-11-02 | $3.71M derived: sum of 2 quarters · filed 2022-11-02 | $5.57M 10-Q · filed 2022-11-02 | $7.42M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-06-30 | $1.85M 10-Q · filed 2022-08-09 | $3.71M 10-Q · filed 2022-08-09 | $5.56M derived: sum of 3 quarters · filed 2024-03-14 | $7.41M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-03-31 | $1.86M 10-Q · filed 2022-05-04 | $3.71M derived: sum of 2 quarters · filed 2024-03-14 | $5.55M derived: sum of 3 quarters · filed 2024-03-14 | $7.42M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2020-12-31 | $1.85M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $3.69M derived: sum of 2 quarters · filed 2024-03-14 | $5.56M derived: sum of 3 quarters · filed 2024-03-14 | $7.39M 10-K/A · filed 2024-03-14 | |
| 2020-09-30 | $1.84M 10-Q · filed 2021-11-04 | $3.71M derived: sum of 2 quarters · filed 2021-11-04 | $5.54M 10-Q · filed 2021-11-04 | $7.45M derived: sum of 4 quarters · filed 2022-02-23 | |
| 2020-06-30 | $1.87M 10-Q · filed 2021-08-04 | $3.74M 10-Q · filed 2021-08-04 | $5.61M derived: sum of 3 quarters · filed 2022-02-23 | $6.98M derived: sum of 4 quarters · filed 2022-02-23 | |
| 2020-03-31 | $1.87M 10-Q · filed 2021-05-05 | $3.74M derived: sum of 2 quarters · filed 2022-02-23 | $5.11M derived: sum of 3 quarters · filed 2022-02-23 | $6.46M derived: sum of 4 quarters · filed 2022-02-23 | |
| 2019-12-31 | $1.87M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $3.24M derived: sum of 2 quarters · filed 2022-02-23 | $4.60M derived: sum of 3 quarters · filed 2022-02-23 | $5.95M 10-K · filed 2022-02-23 | |
| 2019-09-30 | $1.37M 10-Q · filed 2020-11-04 | $2.73M derived: sum of 2 quarters · filed 2020-11-04 | $4.08M 10-Q · filed 2020-11-04 | ||
| 2019-06-30 | $1.35M 10-Q · filed 2020-08-05 | $2.71M 10-Q · filed 2020-08-05 | |||
| 2019-03-31 | $1.35M 10-Q · filed 2020-05-06 | ||||
| 2018-12-31 | $1.86M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |